Kate Hudson - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Kate Hudson's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Kate Hudson
Verified
Associate Editor, BioPharmaJournal.com
Beats
Biology, Evolution , Health, Science Policy, Physics , Science
Others
Content
ZenaTech, Inc. (ZENA): Revolutionizing Defense and Enterprise Solutions with NDAA-Compliant AI Drones
By Kate Hudson, Wall Street| BioPharmaJournal.com@ News Alert: Citius Pharmaceuticals Receives FDA Approval For LYMPHIR™ (Denileukin Diftitox-Cxdl) Immunotherapy For The Treatment Of Adults With Relapsed Or Refractory Cutaneous T-Cell Lymphoma. Click to Read More. ZenaTech, Inc. (Nasdaq: ZENA), a leader in AI-powered drone solutions and enterprise SaaS platforms, has taken a monumental step forward in its strategic growth.
RadNet, Inc. (RDNT): Strategic Collaboration with GE HealthCare Boosts Stock by 21% Amid Advancements in AI-Powered Imaging Solutions
By Kate Hudson, Wall Street| BioPharmaJournal.com@ News Alert: Citius Pharmaceuticals Receives FDA Approval For LYMPHIR™ (Denileukin Diftitox-Cxdl) Immunotherapy For The Treatment Of Adults With Relapsed Or Refractory Cutaneous T-Cell Lymphoma. Click to Read More. RadNet, Inc. (Nasdaq: RDNT), a leader in diagnostic imaging services, experienced a significant surge in its stock price, climbing 20.98% to $87.73 as of mid-afternoon trading on November 11, 2024.
ZenaTech, Inc. (ZENA): Revolutionizing Defense and Enterprise Solutions with NDAA-Compliant AI Drones
By Kate Hudson, Wall Street| BioPharmaJournal.com@ News Alert: Citius Pharmaceuticals Receives FDA Approval For LYMPHIR™ (Denileukin Diftitox-Cxdl) Immunotherapy For The Treatment Of Adults With Relapsed Or Refractory Cutaneous T-Cell Lymphoma. Click to Read More. ZenaTech, Inc. (Nasdaq: ZENA), a leader in AI-powered drone solutions and enterprise SaaS platforms, has taken a monumental step forward in its strategic growth.
Company Info
BioPharmaJournal.com